|
|
Article: FOSAMAX Once-Weekly U.S. Patent Upheld.
- Article from:
- Business Wire
- Article date:
- August 28, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Aug. 28, 2003
Merck & Co., Inc. announced today that the U.S. District Court in Wilmington, Del., upheld Merck's U.S. patent covering the weekly administration of FOSAMAX(R) (alendronate sodium) Once-Weekly. As a result of the court's decision, the patent is valid and infringed by Teva Pharmaceuticals USA, Inc.'s Abbreviated New Drug Application (ANDA) filing. Merck filed a patent infringement lawsuit against Teva in January 2001. The FOSAMAX Once-Weekly patent expires in July 2018. The court's decision is subject to appeal.
FOSAMAX is the world's leading ...